Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -30.94% is 31% below its 5-year average of -23.56%, around the middle of its 5-year range (-60.67%–-2.68%).
As of the fiscal period ended Monday, June 30, 2025. 28.86% below its 12-month average of -24.01%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2025-12-31): -9.30%.
RETURN ON ASSETS (ROA)
-30.94%
RETURN ON ASSETS (ROA) AVG TTM
-24.01%
RETURN ON ASSETS (ROA) AVG 3Y
-19.50%
RETURN ON ASSETS (ROA) AVG 5Y
-23.56%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-28.86%
CURRENT VS 3Y AVG
-58.67%
CURRENT VS 5Y AVG
-31.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+4.03%
vs the sector median at left
Gelteq Limited Ordinary Shares
Market Cap
$5.23M
Return on Assets (ROA)
-30.94%
TTM Avg
-24.01%
3Y Avg
-19.50%
5Y Avg
-23.56%
Market Cap
$5.23M
Return on Assets (ROA)
-106.49%
TTM Avg
-259.99%
3Y Avg
-586.63%
5Y Avg
-434.16%
Market Cap
$5.21M
Return on Assets (ROA)
-1300.98%
TTM Avg
-1108.45%
3Y Avg
-604.75%
5Y Avg
-486.62%
Market Cap
$5.28M
Return on Assets (ROA)
-123.63%
TTM Avg
-110.43%
3Y Avg
-77.11%
5Y Avg
-65.55%
Market Cap
$5.34M
Return on Assets (ROA)
-97.52%
TTM Avg
-106.09%
3Y Avg
-92.87%
5Y Avg
-84.52%
Market Cap
$5.24M
Return on Assets (ROA)
-104.10%
TTM Avg
-116.11%
3Y Avg
-102.15%
5Y Avg
-84.67%
Market Cap
$5.12M
Return on Assets (ROA)
-367.93%
TTM Avg
-1046.51%
3Y Avg
-534.79%
5Y Avg
-427.52%
Market Cap
$5.00M
Return on Assets (ROA)
-98.17%
TTM Avg
-154.79%
3Y Avg
-120.06%
5Y Avg
-94.26%
Market Cap
$5.06M
Return on Assets (ROA)
-71.72%
TTM Avg
-29.50%
3Y Avg
-8.92%
5Y Avg
-8.92%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gelteq Limited Ordinary Shares (GELS) | $5.23M | -30.94% | -24.01% | -19.50% | -23.56% |
| Alzamend Neuro Inc (ALZN)vs › | $5.23M | -106.49% | -259.99% | -586.63% | -434.16% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | -1300.98% | -1108.45% | -604.75% | -486.62% |
| Pulmatrix, Inc. (PULM)vs › | $5.28M | -123.63% | -110.43% | -77.11% | -65.55% |
| Soligenix, Inc. (SNGX)vs › | $5.34M | -97.52% | -106.09% | -92.87% | -84.52% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -104.10% | -116.11% | -102.15% | -84.67% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.12M | -367.93% | -1046.51% | -534.79% | -427.52% |
| Imunon, Inc. (IMNN)vs › | $5.00M | -98.17% | -154.79% | -120.06% | -94.26% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.06M | -71.72% | -29.50% | -8.92% | -8.92% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.95M | -161.71% | -175.21% | -164.83% | -138.13% |
ROA
-30.9%
ROE
-42.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-06-30 | -30.94% |
| 2024-06-30 | -17.08% |
| 2023-06-30 | -15.59% |
| 2022-06-30 | -14.39% |
| 2021-06-30 | -2.68% |
| 2020-06-30 | -60.67% |
